Arcturus Therapeutics
ARCT
130 hedge funds and large institutions have $578M invested in Arcturus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 43 reducing their positions, and 24 closing their positions.
117% more call options, than puts
Call options by funds: $16.6M | Put options by funds: $7.64M
5.62% more ownership
Funds ownership: 75.71% → 81.33% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 43
6% less funds holding
Funds holding: 139 → 130 (-9)
21% less capital invested
Capital invested by funds: $736M → $578M (-$158M)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$29.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.9M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.64M |
| 4 |
Morgan Stanley
New York
|
+$3.63M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$5.77M |
| 2 |
D.E. Shaw & Co
New York
|
-$4.75M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.27M |
| 4 |
Citigroup
New York
|
-$2.13M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.8M |
ARCT Hedge Fund Activity: Q1 2022 in Review
130 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2022, worth a combined $578M — down 21% from $736M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ARCT and 16 opened new positions — a net loss of 8 holders — while 43 trimmed existing stakes and 40 added.
The largest buyer was State Street, adding an estimated $29.6M. The largest seller was ACT Capital Management, cutting an estimated $5.77M.
- 130 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2022, down from 139 in Q4 2021.
- Funds reported $578M of Arcturus Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
- 16 funds opened new Arcturus Therapeutics positions in Q1 2022 and 24 closed out, a net change of -8 holders.
- The largest Arcturus Therapeutics buyer in Q1 2022 was State Street, an estimated $29.6M added.
- The largest Arcturus Therapeutics seller in Q1 2022 was ACT Capital Management, an estimated $5.77M sold.
Based on aggregated 13F filings for Q1 2022.